25- Case Study: A Drug Discovery Success (S2E10)

Welcome back everybody for another deep dive.
And this time, we're gonna get into like a real
world detective story. Oh, cool. Yeah, it's the
journey of a successful HIV protease inhibitor
drug. Okay. and we are gonna go through all the
stages of drug discovery. So from identifying
the target to actually optimizing the final product.
And to make things even more interesting, we're
gonna compare this success story to a drug that...
Well, didn't quite make it. Oh, interesting.
Yeah, it's a great way to see what separates
the winners from the... From the losers. Yeah,
let's say the not -so -winners in this world
of high -stakes. Right, high -stakes research.
Exactly. So let's start with the basics. Okay.
What is HIV protease? Okay. And why was it such
a promising target for researchers battling HIV?
HIV protease is an enzyme and it's essential
for the virus to replicate. OK. So without it,
new virus particles can't mature and spread.
So think of it kind of like a crucial worker
on the HIV production line. OK. You knock out
that worker, you halt the entire factory. So
disrupting HIV protease could like effectively
stop the virus in its tracks. Yes. Did research
back this up? Yeah, absolutely research published
in the late 1980s particularly studies like the
one by Kramer at all in 1989 showed that Inhibiting
HIV protease could block the virus in lab settings.
So this was you know a major breakthrough Yeah,
and a huge validation of HIV protease as a target
for drug development. Okay, so target validated
Yes, I imagine that sparked a lot of excitement
in the research community. Oh, yeah, but Then
comes the real challenge. How do you actually
design a drug to do that, to block HIV protein?
Right. So the initial design phase involved understanding
the structure of HIV proteins and its mechanism
of action. So researchers relied heavily on techniques
like x -ray crystallography and computer modeling
to visualize the enzyme's active site, the region
where it binds to its substrate. It's like trying
to design a key for a lock you've never seen
before. Exactly. But with incredibly high stakes.
Yeah, you need a key that fits perfectly. Right.
Blocks the lock, but doesn't accidentally open
any other locks in the process. Right, of course,
yeah. Scientists needed a molecule that bound
specifically to HIV protease and interfered with
its function without affecting other important
enzymes in the body. So they had to find a molecule
that was both potent and selective. Yes. What
were some of the early approaches they used to
tackle this? So one of the earliest approaches
involved mimicking the natural substrate of HIV
protease, the molecule it normally interacts
with. So the idea was to design a molecule that
resembled the substrate closely enough to bind
to the enzyme, but different enough to prevent
it from functioning properly. So it's like a
decoy, tricking the enzyme into binding to it
instead of its intended target. Exactly. So researchers
designed peptidomimetic inhibitors, molecules
that mimic the peptides normally cleaved by HIV
proteins. Got it. And these early inhibitors,
like the one described by Roberts et al in 1990,
showed some promise, but they faced challenges
with stability and bioavailability. Bioavailability,
that means how well the drug is absorbed and
reaches its target in the body, right? That's
right. It's not enough for a drug to be effective
in a test tube. It needs to reach its destination
in the body at sufficient concentrations. Right.
Yeah. So they had a promising starting point,
but there were definitely hurdles to overcome.
Yeah. It's like having a rough sketch of the
key, but needing to refine it, make it more robust
and durable. Yeah. This is where lead optimization
comes in, right? Exactly. This stage is all about
fine tuning the drug molecule. OK. Tweaking its
structure to enhance its potency, selectivity,
and bioavailability. Uh -huh. It involves a lot
of trial and error testing, different modifications,
and analyzing their effects. So let's imagine
they have a few promising lead compounds. How
do they go about optimizing them? Sounds like
a delicate balancing act. It is. Think of it
like adjusting a recipe. OK. You might add a
pinch of this, a dash of that. Right. Constantly
tasting and refining until you achieve the perfect
balance of flavors. Yeah. In drug development,
researchers make subtle changes to the chemical
structure of the lead compound. OK. Adding or
removing functional groups, tweaking its shape,
or even modifying its overall size. And each
modification is like a tiny experiment, seeing
how it affects the drug's behavior, right? Yes.
testing how well it binds to the enzyme, how
stable it is in the body, how it's metabolized,
and so on. It's a constant process of testing,
analyzing, and refining, driven by data and guided
by a deep understanding of chemistry and biology.
And as we explore the specific modifications
made to this successful HIV protease inhibitor,
you'll see just how intricate this process can
be. This is where the real detective work comes
in. You have to follow the clues, rule out the
dead ends. and potentially hopefully crack the
case. Exactly, and to add another layer of intrigue
to our story, we'll also be looking at a drug
that went through a similar process, but didn't
quite make it to the finish line. That's what
I'm really curious about. What makes one drug
successful, while another seemingly similar one
falls short? I'm ready to hear all about it.
Let's dive into the specifics of our successful
drug. Okay. You know, it went through this rigorous...
lead optimization, and one of the key challenges
was improving its bioavailability. Early versions
of the drug weren't absorbed well in the digestive
system, so this limited their effectiveness.
So how did they tackle that? Did they change
the drug's formulation or try, like, a different
delivery method? They explored several avenues.
One strategy involved modifying the drug's chemical
structure to increase its solubility and permeability.
For instance, they introduced lipophilic groups,
which essentially made the drug molecule friendlier
to fats, allowing it to pass through cell membranes
more easily. It's like giving the drug molecule
a special passport to cross borders more efficiently.
Exactly. I like that. These modifications, as
described in Kemp et al. in 1995, significantly
boosted the drug's oral bioavailability, making
it much more effective when taken as a pill.
That's a huge win. It is. But bioavailability
is just one piece of the puzzle. Right. What
about other aspects like potency and selectivity?
Yeah. Were there any modifications made to enhance
those? Absolutely. Researchers found that by
adding certain chemical groups to the drug molecule,
they could enhance its binding affinity to HIV
protease, making it a more potent inhibitor.
For example, incorporating a hydroxyethylene
moiety, as reported by Vaca et al. in 1994, significantly
increased the drug's ability to block the enzyme.
So they were essentially fine -tuning the key.
to fit the lock even more snugly, preventing
the enzyme from doing its job. Exactly. But what
about selectivity? How did they ensure that the
drug targeted HIV proteins specifically? and
didn't interfere with other enzymes in the body.
Selectivity is crucial to minimize side effects.
Researchers carefully analyzed the drug's interactions
with other enzymes, looking for any off -target
binding. They made strategic modifications to
minimize these interactions. For instance, they
found that by replacing a certain bulky group
with a smaller one, they could reduce the drug's
affinity for a related enzyme, improving its
selectivity. It's like fine -tuning a music instrument,
making sure each note is clear and distinct with
no unwanted dissonance. That's a great analogy.
Thanks. Through these meticulous modifications,
they sculpted the drug molecule into a highly
potent selective and bioavailable weapon against
HIV protease. Wow. But now let's turn our attention
to the failed drug, the one that didn't quite
make the cut. The cautionary tale. This drug
also targeted HIV protease, right? Yes, it did.
What went wrong in its development? Did it stumble
at a particular stage or was it a combination
of factors? This drug went through a similar
design process and early studies showed promise.
It exhibited good binding affinity to HIV protease
and even demonstrated some antiviral activity
in lab tests. So it seemed like they were on
the right track. What happened? The problem emerged
during clinical trials. It turned out that this
drug had a major drawback. It was rapidly metabolized
in the liver. body's detoxification center. It's
like having a highly trained cleanup crew that's
a bit too efficient, removing the drug before
it can do its justice. Exactly. The drug was
broken down so quickly that it couldn't reach
therapeutic concentrations in the bloodstream.
Wow. So despite its initial promise, its rapid
metabolism rendered it ineffective in patients.
So it's a classic case of a drug that looked
good on paper, but failed the real world test.
Precisely. This highlights the importance of
understanding a drug's pharmacokinetic properties.
How it's absorbed, distributed, metabolized,
and excreted. Even if a drug binds perfectly
to its target, if it can't reach that target
in the body at sufficient levels, it's destined
to fail. It's a crucial reminder that drug discovery
is not just about finding a molecule that hits
the target. It's about understanding the entire
journey that drug takes within the body. Absolutely.
And as we've seen comparing these two drugs,
one a resounding success, and the other a disappointing
failure, helps us understand the critical factors
that separate triumph from defeat in the world
of drug development. So our Goldilocks drug,
with its optimized potency, selectivity, and
bioavailability, emerged victorious. It did.
What about its impact? How did it change the
landscape of HIV treatment? So this drug really
did arrive kind of like a knight in shining armor.
It did. It was a game changer. It marked a turning
point in the fight against HIV AIDS. It did.
It wasn't a cure, but it offered something incredibly
valuable. Yes. Hope, exactly. So tell me a little
more about that. So it was one of the first HIV
protease inhibitors to demonstrate this remarkable
efficacy in clinical trials. OK. And the results
were striking patients taking this drug experienced
a significant reduction in viral load, a measure
of the amount of HIV in the blood. OK. And in
many cases, the virus became undetectable. Wow.
So it's like pushing the virus into hiding, giving
the immune system a chance to recover. Exactly.
translated into tangible benefits for patients.
They were less likely to develop opportunistic
infections, those infections that take advantage
of a weakened immune system. So their overall
health improved and their life expectancy increased
dramatically. So it wasn't just about adding
years to life. It was about adding life to years.
Exactly. Transforming HIV AIDS from a death sentence
to a manageable chronic condition. Precisely.
This drug, along with other protease inhibitors
that followed, truly did revolutionize HIV treatment.
It did. It ushered in the era of heart. Yes.
Highly active antiretroviral therapy, a combination
therapy that targets different stages of the
HIV lifecycle. That's right. It's like a multi
-pronged attack hitting the virus from multiple
angles, making it much harder for it to develop
resistance. And this approach has been incredibly
successful. It has. Heart has significantly reduced
the incidence of AIDS -related deaths and has
dramatically improved the quality of life for
millions of people living with HIV worldwide.
Absolutely. The testament to the power of scientific
research. It is. And a reminder that even in
the face of seemingly insurmountable challenges,
breakthroughs can happen. Yes. But as we've seen
with the failed drug, the journey is not always
smooth. Right. What are some of the ongoing challenges
in HIV drug development? So one of the biggest
hurdles remains drug resistance. HIV is a highly
mutable virus, constantly changing and adapting.
It can develop mutations that make it less susceptible
to the drugs we use against it. So it's like
this constant arms race. Yes. Trying to stay
ahead of the virus as it evolves. That's a great
way to put it. Researchers are constantly working
to develop new drugs that can overcome resistance.
Okay. Exploring novel targets within the virus
and designing drugs with different mechanisms
of action. So it's a continuous process of innovation
driven by the need to stay one step ahead of
this formidable foe. It is. What about the future?
What's on the horizon for HIV treatment and prevention?
The research landscape is incredibly exciting.
Scientists are working on long -acting injectable
formulations of antiretroviral drugs, which could
reduce the burden of daily pill taking. There's
also a lot of research focused on gene editing
techniques, exploring the possibility of actually
removing HIV from infected cells. That sounds
like science fiction becoming reality. It does,
doesn't it? And what about preventative measures?
Are there any new developments in that area?
Pre -exposure prophylaxis, or pre -AP, has been
a major breakthrough in HIV prevention. It involves
taking antiretroviral drugs daily to reduce the
risk of contracting HIV. Newer pre -REPE medications
are even more effective and have fewer side effects.
There's also ongoing research into developing
a vaccine for HIV, which would be a game changer
in the fight against the virus. So while there
are still challenges, there's also immense hope
for the future. Absolutely. The progress we've
made in HIV treatment and prevention is a testament
to the power of scientific ingenuity, collaboration,
and perseverance. I couldn't agree more. And
it's a reminder that scientific research can
truly make a difference in people's lives. Yeah.
It's a story of triumph over adversity, a story
that continues to unfold as we strive to create
a world free from HIV AIDS. We've covered a lot
of ground today. We have. From the intricate
molecular details of HIV protease to the transformative
impact of a successful drug and the ongoing challenges
that lie ahead. Yes. What's the one key takeaway
you'd like our listener to ponder as they go
about their day? I'd say the story of HIV drug
development is a powerful example of how scientific
curiosity, rigorous research, and a deep understanding
of both chemistry and biology can lead to life
-saving breakthroughs. It's a story that highlights
the importance of continued investment in scientific
research and the potential for science to change
the world for the better. Beautifully said. It's
a story that inspires hope. and underscores the
power of human ingenuity. Thanks for joining
us on this fascinating deep dive. It was my pleasure.
Until next time, stay curious and keep exploring.